Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round garners $40mm for Anokion concurrent with Kanyos acquisition

Executive Summary

Anokion SA (autoimmune disease drug development) raised $40mm through its Series B round from investors including Versant Ventures, Novartis Venture Fund, Novo Ventures, Celgene, and undisclosed Swiss private investors. Anokion also announced the acquisition of Kanyos Bio, a firm it spun out in 2015 to develop celiac disease and diabetes candidates. Series B proceeds will support development of Anokion's preclinical pipeline which includes its own ANK780 for multiple sclerosis, and KAN101, which it gains from Kanyos and will continuing developing for celiac disease.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies